低分子肝素钙在预防过敏性紫癜肾脏损害中的作用

目的观察低分子肝素钙在预防小儿过敏性紫癜肾损害中的作用。方法将85例患儿随机分为治疗组（44例）和对照组（41例），治疗组给予低分子肝素钙60～100U／kg，皮下注射，1日1次，连用2周。结果两组随访时间均为3个月以上。治疗1个月及3个月后治疗组尿微量白蛋白（MALB）、尿α-微球蛋白（α—MG）均显著低于对照组（P均〈0．01）；治疗组与对照组肾炎发生率分别为17．14％（6／35）和42．86％（12／28），两组差异有显著性意义（χ^2=3．875，P〈0．05）；发生肾炎的时间治疗为发病后（91．5±43．7）d，对照组为发病后（43．9±33．5）d，前者明显晚于后者（t=5．26，P〈0．001）。结论肝素能预防或减少紫癜性肾炎的发生，具有显著的肾脏保护作用。

Effect of Low Molecular Heparin Calcium in Prevention of Henoch-Schonlein Purpura Nephritis

Objective To evaluate the therapeutical effect of low molecular heparin calcium in the prevention of Henoch- Schonlein purpura nephritis （HSPN）. Methods The 85 children with Henoch-Schonlein purpura （HSP） were divided into the treatment group （44 cases） and the control group（41 cases） at random. Low molecular heparin calcium 60- 100 U/kg was injected subcutaneously, once daily, for two weeks in the treatment group. Fundamental treatment of two groups was same in the treatment period. The urinary microalbumin（MALB） and α-microglobulin（α- MG）were assayed at admission, a month and three months after treatment. Results All patients were followed for at least 3 months. The urinary MALB and α- MG were not significantly different at admission and significantly different at a month and three months between two groups, significantly lower in treated group than control group. Nephritis was noted in 12 （42.86%）cases in the control group, whereas only 6 （17. 14% ）cases in the treated group （χ^2 =3. 875, P 〈0. 05）. Nephritis occurred latter in the treatment group [（91.5±43.7）d] than the control group[（43.9±33.5）d]（t=5.26, P 〈 0. 001）. Conclusion Heparin could significantly reduce the incidence of HSPN and has obvious renal protective effect.